GWM Advisors LLC lifted its holdings in Iqvia Holdings Inc (NYSE:IQV) by 12.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,664 shares of the medical research company’s stock after purchasing an additional 647 shares during the quarter. GWM Advisors LLC’s holdings in Iqvia were worth $815,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of IQV. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Iqvia by 7.0% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,251 shares of the medical research company’s stock valued at $1,331,000 after acquiring an additional 608 shares during the last quarter. Advisory Services Network LLC raised its position in Iqvia by 37.4% in the 4th quarter. Advisory Services Network LLC now owns 5,825 shares of the medical research company’s stock valued at $677,000 after buying an additional 1,587 shares during the last quarter. MUFG Securities EMEA plc grew its stake in Iqvia by 2,517.2% in the 4th quarter. MUFG Securities EMEA plc now owns 115,000 shares of the medical research company’s stock valued at $13,360,000 after purchasing an additional 110,606 shares during the period. Globeflex Capital L P grew its stake in Iqvia by 96.6% in the 1st quarter. Globeflex Capital L P now owns 10,784 shares of the medical research company’s stock valued at $1,551,000 after purchasing an additional 5,299 shares during the period. Finally, Meridian Wealth Advisors LLC grew its stake in Iqvia by 13.0% in the 1st quarter. Meridian Wealth Advisors LLC now owns 4,197 shares of the medical research company’s stock valued at $604,000 after purchasing an additional 482 shares during the period. Institutional investors own 89.78% of the company’s stock.
In other Iqvia news, insider Ari Bousbib sold 96,000 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $140.96, for a total transaction of $13,532,160.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Evanisko sold 1,193 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $144.95, for a total value of $172,925.35. The disclosure for this sale can be found here. Insiders have sold 143,273 shares of company stock valued at $20,066,890 in the last three months. 6.00% of the stock is currently owned by corporate insiders.
Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, May 1st. The medical research company reported $1.53 EPS for the quarter, beating analysts’ consensus estimates of $1.41 by $0.12. The company had revenue of $2.68 billion during the quarter, compared to analysts’ expectations of $2.67 billion. Iqvia had a return on equity of 15.08% and a net margin of 2.35%. Iqvia’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.34 earnings per share. As a group, research analysts anticipate that Iqvia Holdings Inc will post 5.88 earnings per share for the current year.
Several research analysts have commented on IQV shares. UBS Group set a $170.00 target price on Iqvia and gave the stock a “buy” rating in a research note on Friday, February 15th. Barclays raised their price objective on Iqvia from $160.00 to $167.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Wells Fargo & Co raised their price objective on Iqvia from $140.00 to $160.00 and gave the company an “outperform” rating in a report on Tuesday, February 19th. Piper Jaffray Companies lifted their price target on Iqvia to $148.00 and gave the stock a “neutral” rating in a research note on Friday, February 15th. Finally, Leerink Swann assumed coverage on Iqvia in a research report on Tuesday, May 28th. They issued an “outperform” rating and a $136.38 price objective on the stock. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and a consensus target price of $147.02.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.themarketsdaily.com/2019/06/14/gwm-advisors-llc-buys-647-shares-of-iqvia-holdings-inc-nyseiqv.html.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading: What is the price-sales ratio?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.